Associazione Italiana contro Leucemie, Linfomi e Mieloma
Age
25–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with previous diagnosis of classic Hodgkin Lymphoma (cHL) or Diffuse Large B Cell Lymphoma (DLBCL) or Primary Mediastinal B Cell Lymphoma (PMBCL).
Patients in complete remission after first line anthracycline containing regimen (ABVD, BV-AVD, BEACOPP, R-CHOP, Pola-R-CHP o R-DA-EPOCH) +/- radiotherapy.
Age ≥ 25 and ≤ 55 at enrollment.
Patients between third and fifth year of follow-up after the end of the first line treatment.
Absence of signs or symptoms of disease relapse.
You may not be if
Patients with CNS disease localization.
Patients that received brain/neuroaxis radiotherapy.
Pre-existing severe psychiatric or neurologic comorbidities influencing neurocognitive assessment.
Clareo Health | Neurocognitive Assessment in Long-Term Survivors of Lymphoma
